VIOQUEST INITIATES CLINICAL TRIAL FOR VQD-002

VioQuest Pharmaceuticals has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P).

This trial is being conducted in up to 20 patients with diverse solid tumors, where abnormal levels of phosphorylated Akt (protein kinase B) have been observed.